Immunoengineering represents a cutting-edge interdisciplinary domain that utilizes engineering tools to interrogate and modulate the immune system with unprecedented precision. This modulation involves either enhancing immune responses, as needed in cases of cancer or viral infections, or dampening them to treat autoimmune conditions. OCIE’s approach leverages this dual capability, seeking to systematically dissect immune mechanisms and develop innovative treatments tailored to diverse pathological contexts. The center is spearheaded by Wei Chen, Ph.D., an expert in cancer immunotherapy, and Chongle Pan, Ph.D., a leader in data science and computational biology, underscoring the center’s commitment to combining experimental and computational methodologies.

A critical infrastructure component of OCIE is the establishment of two synergistic research cores. The Immunomodulation Technology Core focuses on experimental laboratory work, providing researchers with advanced tools and methodologies to probe immune responses at the molecular and cellular levels. This core facilitates the development of novel immunotherapeutic strategies by enabling manipulation of immune cells and pathways in controlled laboratory settings. Complementing this, the Omics Data Science Core brings to bear state-of-the-art computational techniques and bioinformatics expertise. This core is dedicated to designing experiments, managing large-scale omics datasets, and applying machine learning algorithms to derive predictive models from complex immune system data.

The importance of integrating high-dimensional omics data with immunological experimentation arises from the sheer volume and complexity of information generated by modern biomedical research. Immunoengineering studies produce vast arrays of data spanning genomics, transcriptomics, proteomics, and metabolomics, which require sophisticated analytics to unravel the underlying biological insights. Through the synergy of experimental and computational cores, OCIE aims to build predictive frameworks that can forecast immune behavior under various therapeutic interventions, a critical step toward personalized medicine.

Dr. Wei Chen, leading the center, emphasizes the transformative potential of this integrated platform. Chen highlights his personal research in immunotherapy for late-stage cancer patients where the amalgamation of immunological insights with omics-driven data analysis has yielded innovative therapeutic avenues. OCIE aspires not only to be a hub of scientific innovation but also to serve as a collaborative platform for researchers across Oklahoma, fostering an ecosystem where discoveries rapidly translate into clinical applications that improve patient outcomes. This endeavor is positioned as a pioneering center nationally, with no existing comparable entity focusing on the convergence of immunomodulation and omics data science.

The Omics Data Science Core, under Chongle Pan’s guidance, is focused on harnessing artificial intelligence (AI), predictive modeling, and machine learning to provide actionable intelligence from immune system datasets. Because immune responses are highly dynamic and context-dependent, understanding them requires more than descriptive analysis—it requires predictive models that can simulate immune responses and predict therapeutic success. Pan’s work aims to democratize access to these computational tools, enabling researchers statewide to maximize the scientific yield of their immune-related studies.

OCIE also prioritizes the development of future scientific leaders by selecting and mentoring early-career investigators. Four junior faculty members have been appointed as research project leaders, each matched with experienced mentors from OU’s Norman and Health Sciences campuses. These young scientists spearhead innovative projects encompassing a broad range of immunoengineering challenges—from bat immunology related to coronavirus infection to sophisticated neuroimaging-guided immunotherapy in brain cancer, to computational and molecular investigations aimed at novel cancer vaccine design and understanding rare sarcoma immune microenvironments.

One project, led by Dr. Daniel Becker, explores the immune response of migratory bats to coronavirus infections, potentially offering vital clues to host-pathogen dynamics and natural viral resistance mechanisms. Dr. David Miller’s research focuses on glioblastoma, employing neuroimaging to guide immunotherapy approaches for one of the most aggressive and lethal brain tumors. Marmar Moussa’s work delves into T-cell receptor and antigen interactions, a fundamental aspect of developing effective peptide-based cancer vaccines. Meanwhile, Dr. Abdul Rafeh Naqash studies alveolar soft part sarcoma’s tumor immune microenvironment, identifying molecular vulnerabilities that could be therapeutically targeted.

Beyond project-specific research, OCIE fosters a vibrant scientific community through monthly seminars, interactive research roundtables, hands-on training workshops, and an annual symposium designed to catalyze interdisciplinary collaboration. A core mission of the center is to fund pilot research and promote team science, connecting basic immunologists, translational scientists, and clinicians to accelerate the journey from bench to bedside. This integrative approach aims to dismantle traditional silos and facilitate comprehensive understanding and manipulation of immune responses in multiple disease contexts.

The establishment of OCIE arrives at a strategic moment, given Oklahoma’s inclusion among the states benefiting from the NIH Institutional Development Award (IDeA) program. This program aims to enhance the research infrastructure in states that historically have received lower levels of NIH funding, thereby expanding national biomedical research capacity and equity. Through OCIE, Oklahoma becomes a vanguard for immunoengineering, reinforcing its scientific stature and capacity for biomedical innovation.

OCIE’s vision is nothing short of revolutionary. By converging immunology, engineering, and data science, the center establishes a model for precision immunomodulation. With capabilities spanning experimental manipulation and bioinformatic modeling, OCIE situates itself at the frontier of modern biomedicine, promising breakthroughs that could redefine immune system-based therapies. The center epitomizes the future of interdisciplinary biomedical research—where computation and experimentation coalesce to decode the immune system’s complexities and unlock new therapeutic vistas.

In summary, the University of Oklahoma’s Oklahoma Center for ImmunoEngineering leverages substantial NIH investment to create an unprecedented platform that integrates experimental immunomodulation technologies with advanced omics data science. Co-led by Drs. Wei Chen and Chongle Pan, OCIE is poised to make transformative advances in understanding and controlling immune function over diverse diseases such as cancer, viral infections, and autoimmune disorders. By supporting a new generation of interdisciplinary scientists and fostering collaboration, OCIE heralds a new era in immunoengineering, setting the stage for discoveries that hold the promise of vastly improved human health outcomes.

Subject of Research: Immunoengineering, Immunomodulation, Omics Data Science, Immunotherapy, Computational Biology

Article Title: University of Oklahoma Launches Pioneering Oklahoma Center for ImmunoEngineering with $11.5M NIH Award

News Publication Date: Not specified (most recent based on funding announcement)

Web References:
https://mediasvc.eurekalert.org/Api/v1/Multimedia/f8d658b4-8a4c-4e7e-b61d-c04c29ac2b93/Rendition/low-res/Content/Public

Image Credits: Jonathan Kyncl/University of Oklahoma

Keywords: Immunoengineering, Immunomodulation, Immune Regulation, Omics Data Science, Artificial Intelligence, Cancer Immunotherapy, Predictive Modelling, Machine Learning, Immune System, Biomedical Engineering, Systems Biology

Published on March 26, 2026, in the distinguished journal Cell Reports, this study centers on the epigenetic landscape of memory T cells. Unlike naïve T cells, which may take several days to mount a robust defense upon first encounter with a pathogen, memory T cells can activate crucial defense genes within mere hours. This striking difference is encoded in the epigenome—the suite of chemical and structural modifications to DNA and chromatin that influence gene expression without altering the underlying genetic code itself. These modifications finely tune cellular readiness by regulating DNA accessibility and transcriptional responsiveness.

Dr. Emily Miraldi, a computational biologist and senior author of the study, emphasizes how this research transcends previous knowledge. While the phenomenon of rapid immune recall has been recognized, the precise molecular circuitry responsible had remained elusive. Utilizing advanced single-cell genomics combined with gene regulatory network modeling, her team has mapped the intricate web of transcription factors—proteins that bind DNA and orchestrate gene activity—that sustain memory T cells in a heightened state of readiness, primed for swift activation.

The study undertook a detailed single-cell analysis of tens of thousands of human CD4⁺ T cells derived from multiple donors, enabling a granular view of both gene expression profiles and chromatin accessibility patterns. This dual approach allowed the researchers to pinpoint regions of the genome already open and poised for action in resting memory cells. Intriguingly, these regulatory regions remain largely inaccessible in naïve T cells prior to initial activation, underscoring a fundamental epigenomic divergence that equips memory cells for expedited responses.

One key finding revealed that the memory T cells preserve a pre-established chromatin architecture, wherein numerous immune-response gene enhancers and promoters are already exposed and available for transcription factor binding. This structural “head start” accelerates the kinetics of the immune response, permitting these cells to bypass the time-consuming process of chromatin remodeling typically required in naïve cells upon pathogen recognition. Alexander Katko, co-first author and immunobiology PhD candidate, remarks on the significance of this pre-primed state in enabling rapid immune mobilization.

Beyond mapping chromatin landscapes, the investigation identified five critical transcription factors that distinguish memory T cells from naïve cells: KLF6, MAF, PRDM1, RUNX2, and SMAD3. These factors create a robust core regulatory network that not only maintains transcriptional readiness during periods of cellular quiescence but also fuels dynamic transcriptional activation when triggered by antigen re-exposure. Such coordinated regulatory interplay exemplifies the depth of control essential for balanced immune memory function.

Dr. Artem Barski, co-senior author and specialist in allergy, immunology, and human genetics, notes the conceptual leap from viewing immune memory at the level of individual genes to understanding it as an emergent property arising from a complex, interconnected network of regulatory proteins. This systems biology approach provides a framework for decoding how multiple layers of transcriptional regulation collectively govern immune cell behavior, advancing the frontier of immunological research.

Intriguingly, the team integrated their gene regulatory network model with extensive genetic datasets from over a hundred additional individuals, including subjects undergoing peanut oral immunotherapy. This integration revealed that numerous DNA variants associated with asthma, allergic diseases, and autoimmune disorders map to memory-specific regulatory elements rather than protein-coding sequences. Such variants likely modulate the intensity and velocity of immune gene activation, potentially tipping the balance toward harmful hyperactive or dysregulated immune responses.

These findings have profound clinical implications. Understanding the regulatory architecture underlying rapid immune recall offers a blueprint for next-generation vaccine design, especially tailored for populations like the elderly, whose immune responses to conventional vaccines often decline. Vaccines engineered to elicit more responsive memory T cells could dramatically enhance protective efficacy. Simultaneously, these insights could inform precision therapies aimed at dampening pathological immune overactivation without resorting to broad immunosuppression, thus preserving overall immune competence.

The study’s comprehensive approach employed cutting-edge computational simulations alongside experimental single-cell profiling, bridging molecular biology, genomics, and immunology. The research team credits collaborative contributions from experts in allergy and immunology, human genetics, and the Single Cell Genomics Facility at Cincinnati Children’s, as well as strong support from multiple NIH grants, underscoring the interdisciplinary and resource-intensive nature of this breakthrough.

Ultimately, this pioneering work lays the foundation for a systems-level understanding of immune memory, illuminating how epigenetic programming and transcriptional regulatory networks empower memory CD4⁺ T cells for rapid antigen recall. Such knowledge is poised to accelerate advances in immunotherapies and vaccine development and to deepen our grasp of the molecular underpinnings of immune-mediated diseases.

Subject of Research: Not applicable
Article Title: Gene regulatory network determinants of rapid recall in human memory CD4+ T cells
News Publication Date: 26-Mar-2026
Web References: http://dx.doi.org/10.1016/j.celrep.2026.117103
References: Cell Reports, 26 March 2026, DOI: 10.1016/j.celrep.2026.117103
Image Credits: Cincinnati Children’s
Keywords: Health and medicine, Immune disorders, Allergies, Autoimmune disorders, Infectious diseases